IFNG and cervical carcinoma: A phase I trial involving overlapping HPV-16 E6 and E7 peptides with Montanide ISA51 adjuvant in end-stage cervical cancer patients and VIN grade III patients elicited broad IFN-γ associated T-cell responses [145].